Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Recruiting 2Withdrawn 1

Sponsor Class

OTHER_GOV 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 3Sarcoma 1

Conditions

Breast Neoplasms 175HER2-positive Breast Cancer 16Neoplasms 11Neoplasm Metastasis 10Prostatic Neoplasms 7Ovarian Neoplasms 7Stomach Neoplasms 6Carcinoma, Non-Small-Cell Lung 6Pancreatic Neoplasms 5Inflammatory Breast Neoplasms 5Colonic Neoplasms 5Brain Neoplasms 5Triple Negative Breast Neoplasms 4Multiple Myeloma 4Hematologic Neoplasms 4Endometrial Neoplasms 4Colorectal Neoplasms 4Urinary Bladder Neoplasms 3Solid Tumor 3Rectal Neoplasms 3Pathologic Complete Response 3Lymphoma, Non-Hodgkin 3Lung Neoplasms 3HER2-positive Early Breast Cancer 3Esophageal Neoplasms 3Breast Neoplasms, Male 3Biliary Tract Neoplasms 3Anatomic Stage I Breast Cancer AJCC v8 3Salivary Gland Neoplasms 2Locally Advanced Breast Cancer 2

Interventions

Carboplatin 7Trastuzumab 6Docetaxel 5pembrolizumab 4Paclitaxel 4Oxaliplatin 4Fluorouracil 4Cytarabine 4Cyclophosphamide 4Azacitidine 4pertuzumab 3Radiotherapy 3Epirubicin 3Cisplatin 3Chemoradiotherapy 3Capecitabine 3venetoclax 2toripalimab 2sargramostim 2olaparib 2durvalumab 2cc-486 2Tretinoin 2Surgical Procedures, Operative 2Standard of Care 2Pemetrexed 2Observation 2Monatide (IMS 3015) 2Metformin 2Leucovorin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Pathologic Complete Response × pertuzumab × Clear all
NCT01042379 2026-05-06

I-SPY

QuantumLeap Healthcare Collaborative

Phase 2 Recruiting
5,000 enrolled
BreastSarcoma

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT06927180 2025-06-23

SHR-A1811 Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BC

Henan Cancer Hospital

Phase 2 Recruiting
180 enrolled
Breast

Pathologic Complete Response, Breast Neoplasms

NCT05474690 2024-02-26

A Study Comparing the Efficacy of TCbHP and ECHP-THP in the Neoadjuvant Treatment of HER2-positive Breast Cancer

Henan Cancer Hospital

Phase 3 Withdrawn
Breast

Pathologic Complete Response, Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡